Clinical trial
A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants
NCT05412030 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy Infants
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 16, 2022
- Completion date
- September 18, 2025
- Enrollment
- 388 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.